Curated News
By: NewsRamp Editorial Staff
March 17, 2025

Pacylex Pharmaceuticals Initiates Clinical Trial for Oral Zelenirstat in AML Patients

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackDiscuss on Telegram TelegramView History of this news story on GitHub Github
Source News Release

TLDR

  • Pacylex Pharmaceuticals leads in N-myristoyltransferase inhibitors (NMTis) for cancer treatment, giving a competitive edge in developing new therapies.
  • Pacylex launches clinical trial of oral zelenirstat in refractory/relapsed AML patients, supported by a grant from US Department of Defense.
  • Pacylex's new clinical trial offers hope for AML patients with potential life-saving treatments, advancing cancer research and patient care.
  • Zelenirstat shows promise in killing AML cancer cells, fueling excitement for its potential impact on cancer treatment.

Impact - Why it Matters

This news highlights a significant advancement in cancer treatment, particularly for AML patients who have limited options. The launch of the clinical trial signifies progress in developing targeted therapies that could potentially improve outcomes and quality of life for individuals battling hematologic cancers.

Summary

Pacylex Pharmaceuticals Inc. announced the launch of a new clinical trial for oral zelenirstat, a targeted therapy for hematologic cancers, specifically refractory/relapsed Acute Myeloid Leukemia (AML) patients. The trial, led by Dr. Naveen Pemmaraju at MD Anderson Cancer Center, is supported by a grant from the US Department of Defense. Phase 1 studies showed promising safety and efficacy results, prompting further investigation in AML patients.

Source Statement

This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Pacylex Pharmaceuticals Initiates Clinical Trial for Oral Zelenirstat in AML Patients

blockchain registration record for the source press release.